Hu et al. also suggested that patients with high expression of both FGF19 and FGFR4 had significantly poor prognoses for ovarian cancer and that FGF19 and FGFR4 signaling could promote ovarian cancer proliferation and invasion through the AKT-MAPK signaling pathway [30]. This evidence concerns the gene AKT1 and ovarian carcinoma.